We developed neurostimulation as the first line of treatment for pharmacoresistant epilepsy patients. We have partnered with a corporate strategic, received CE Mark under MDR regulations, and launched commercially in EU in 2024. We are working with the CEO and CTO of Precisis to hire our Program Man